UPDATE: Galectin Therapeutics Supports Investigational New Drug Application for its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma

Galectin Therapeutics (NASDAQ: GALT ) today announced that Providence Portland Medical Center filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) on December 27, 2013 to study GR-MD-02 in combination with Yervoy® (ipilimumab) in a Phase 1B study of patients with metastatic melanoma.